Outputs

The outputs below represent the collective insights of 38 industry leaders brought together for two days of closed-room discussion at the Cell and Gene Therapy Insights Special Interest Group.

Convened to address the field's most pressing questions on the future of CAR-T cell therapy, the group explored the relative promise of in vivo, allogeneic and autologous modalities, solid tumor efficacy, patient access and regulatory alignment, with findings drawn from structured expert discussion and live polling conducted across both sessions.

New content will be added to this page as outputs are released.

The Future of CAR-T Cell Therapy: Special Interest Group Meeting Report

This report summarizes discussion across 12 working group sessions covering the scientific, manufacturing, clinical, regulatory, and commercial development of CAR-T cell therapy, addressing three modalities – autologous, allogeneic, and in vivo CAR-T. Participants did not identify any single modality as likely to dominate: the choice of modality and manufacturing model was seen to depend on indication and region, with the three formats expected to coexist.

Cost of goods and safety were identified as the principal barriers to patient access, underlying most reimbursement and clinical delivery questions. Standardization was judged achievable for safety-relevant attributes and chain of custody/identity, but limited for product-specific attributes such as potency.

This report sets out where the field stands, what the most experienced people in the sector believe needs to change, and where coordinated action across organizations is both necessary and achievable — giving readers a clear picture of the critical decisions, the available options, and the open questions that remain.

The industry speaks: what is the future of CAR-T cell therapy?

CAR-T cell therapy enters its next decade with hard-won momentum and unresolved challenges in equal measure. The science is advancing. The system has not yet caught up.

This pressing challenge brought together 38 leading experts from industry and academia for an invitation-only event exploring the field's most urgent priorities — captured across six live polls over 2 days.